4BIO Capital Welcomes New Talent to Investment Team
4BIO Capital, a venture capital firm specializing in advanced and emerging therapies, has announced the onboarding of new team members to enhance its investment capabilities. These appointments signal the firm’s commitment to driving innovation in the biotechnology industry and providing transformative therapies to patients around the world.
Exciting New Additions
Recently, Dr. Therese (Thera) Liechtenstein has been appointed as an Investment Director in Munich, while Tay Salimullah joins as a Venture Partner based in Chicago. Their experiences and perspectives in the field promise to add significant value to 4BIO's investment strategy.
Leadership Insights
Dmitry Kuzmin, Managing Partner at 4BIO Capital, expressed enthusiasm about the new additions: "Thera and Tay’s extensive experience and innovative perspectives will be invaluable to 4BIO as we continue to drive forward our mission of investing in transformative therapies. Their diverse thoughts and expertise strengthen our unique edge, positioning us as leaders in the advanced and emerging therapies sector. We eagerly anticipate their contributions to our portfolio and investments."
Thera Liechtenstein's Background
Thera Liechtenstein comes to 4BIO from M Ventures, where she was Senior Investment Director in the Biotechnology team. At M Ventures, she has had a successful track record, leading the creation of companies and spearheading Seed and Series A investments while also being actively involved in board positions. Thera’s educational journey has molded her into a proficient figure in the biotechnology sector; she holds a PhD in Immuno-Oncology from University College London, alongside an MSc in Biomedical Sciences from the University of Amsterdam.
Tay Salimullah's Expertise
Tay Salimullah brings more than 20 years of leadership experience in the MedTech industry, particularly in rare diseases, with a notable history at Novartis. He played an instrumental role in introducing innovative therapies such as Zolgensma and Kymriah, ensuring access to these groundbreaking treatments globally. His vast expertise encompasses drug development, market access, and product commercialization, which will undoubtedly enhance 4BIO's operational strategies. Tay graduated with a BSc in Management Sciences from the University of Brunel in London.
Aiming for Transformative Healthcare Solutions
4BIO Capital's primary goal remains centered on investing in and nurturing early-stage companies focused on curative therapies. The investment firm is currently deploying funds from its third fund, which enjoys backing from several esteemed institutional investors worldwide. By expanding its investment team, 4BIO aims to bolster its reach in the biotech realm while continually striving for advancements in patient care.
About 4BIO Capital
Situated in London, 4BIO Capital is dedicated solely to the advanced therapies sector, uniting experienced life science investors and leading therapy scientists. The company aims to support and scale innovative companies that are crucial for the growth of advanced therapies, such as cell and gene therapy and RNA-based therapies.
For inquiries, please contact 4BIO Capital at +44 (0) 203 427 5500 or via email at info@4biocapital.com.
Frequently Asked Questions
Who are the new appointments at 4BIO Capital?
The new appointments include Dr. Therese Liechtenstein as Investment Director and Tay Salimullah as Venture Partner.
What is the main focus of 4BIO Capital?
4BIO Capital focuses on advanced and emerging therapies, specializing in providing transformative healthcare solutions.
What is the recent experience of Thera Liechtenstein?
Thera Liechtenstein previously worked at M Ventures, leading investments in biotechnology and serving on company boards.
Why are the new appointments significant?
These appointments are expected to provide fresh insights and enhance 4BIO’s strategy in investing in transformative therapies.
How does 4BIO Capital aim to grow?
4BIO Capital aims to grow by investing in early-stage companies passionate about developing innovative therapies and ensuring patient access to curative treatments.
